Abstract
Background: Intraductal papillary mucinous neoplasms (IPMNs) are among the important
premalignant lesions. Early detection and intervention are critical to positive patient outcomes.
Magnetic resonance imaging (MRI) can be used to evaluate the malignancy of IPMNs, and magnetic
resonance cholangiopancreatography (MRCP) is recommended for follow-up of pancreatic
cystic lesions.
Objective: To evaluate the diagnostic performance of MRI combined with MRCP in determining
the malignant potential of pancreas IPMN.
Methods: This is a retrospective study of 55 patients with 58 pancreatic lesions confirmed after
surgery, which were analyzed and divided into two groups, a benign IPMN group (n = 27) and a
malignant IPMN group (n = 31). Two radiologists analyzed the high-risk stigmata and worrisome
features of pancreas IPMN to evaluate the malignant potential. Score all the lesions as proposed by
the international consensus guidelines 2012, and calculate the sensitivity, specificity and accuracy.
Results: There were significant differences of size, enhancement of solid components, and degree
of dilation of the main pancreatic duct between benign and malignant IPMN (P < 0.05). However,
differences in gender, age and location of disease between the two groups were not statistically
significant (P > 0.05). The sensitivity, specificity and accuracy of MRI combined with MRCP in
preoperative diagnosis of malignant IPMNs were 90.3% (28/31), 70.4% (19/27) and 81.0% (47/58)
respectively, when at least one worrisome feature was present.
Conclusion: MRI combined with MRCP is useful in the evaluation of the benign and malignant
pancreas IPMN.
Keywords:
Pancreas, intraductal papillary mucinous neoplasms, magnetic resonance imaging, magnetic resonance cholangiopancreatography,
lesions, patients.
Graphical Abstract
[1]
Op de Beeck B, Spinhoven M, Corthouts B, et al. Management of cystic pancreatic masses. JBR-BTR 2007; 90(6): 482-6.
[2]
Reid-Lombardo KM, St Sauver J, Li Z, et al. Incidence, prevalence, and management of intraductal papillary mucinous neoplasm in Olmsted County, Minnesota, 1984-2005: A population study. Pancreas 2008; 37(2): 139-44.
[3]
Tanaka M, Chari S, Adsay V, et al. International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas. Pancreatology 2006; 6: 17-32.
[4]
Bosman FT, Carneiro F, Hruban RH, et al. WHO classification of tumors of the digestive system. 4th ed. Lyon: IARC 2010.
[5]
Sohn TA, Yeo CJ, Cameron JL, et al. Intraductal papillary mucinous neoplasms of the pancreas: an updated experience. Ann Surg 2004; 239(6): 788-97.
[6]
Hruban R, Pitman MB, Klimstra D. Tumors of the Pancreas, AFIP Atlas of Tumor Pathology, 4th Series Fascicle 6. Washington, DC: America 2007.
[7]
Freeny PC, Saunders MD. Moving beyond morphology: New insights into the characterization and management of cystic pancreatic lesions. Radiology 2014; 272(2): 345-63.
[8]
Tanaka M, Fernández-del Castillo C, Adsay V, et al. International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. Pancreatology 2012; 12(3): 183-97.
[9]
Kim JH, Hong SS, Kim YJ, et al. Intraductal papillary mucinous neoplasm of the pancreas: Differentiate from chronic pancreatits by MRI. Eur J Radiol 2012; 81(4): 671-6.
[10]
Kang KM, Lee JM, Shin CI, et al. Added value of diffusion-weighted imaging to MR cholangiopancreatography with unenhanced MR imaging for predicting malignancy or invasiveness of intraductal papillary mucinous neoplasm of the pancreas. J Magn Reson Imaging 2013; 38(3): 555-63.
[11]
Wang X, Cai YQ, Chen YH. Biliary tract intraductal papillary mucinous neoplasm: Report of 19 cases. World J Gastroenterol 2015; 21: 4261-7.
[12]
Shi C, Hruban RH. Intraductal papillary mucinous neoplasm. Hum Pathol 2012; 43(1): 1-16.
[13]
Kim SH, Lee JM, Lee ES, et al. Intraductal papillary mucinous neoplasms of the pancreas: Evaluation of malignant potential and surgical resectability by using MR imaging with MR cholangiography. Radiology 2015; 274(3): 723-33.
[14]
Ogawa H, Itoh S, Ikeda M, et al. Intraductal papillary mucinous neoplasm of the pancreas: Assessment of the likelihood of invasiveness with multisection CT. Radiology 2008; 248(3): 876-86.
[15]
Jang KM, Kim SH, Min JH, et al. Value of diffusion-weighted MRI for differentiating malignant from benign intraductal papillary mucinous neoplasms of the pancreas. AJR Am J Roentgenol 2014; 203: 992-1000.
[16]
Kim JH, Eun HW, Kim KW, et al. Intraductal papillary mucinous neoplasms with associated invasive carcinoma of the pancreas: Imaging findings and diagnostic performance of MDCT for prediction of prognostic factors. AJR Am J Roentgenol 2013; 201: 565-72.
[17]
Kim KW, Park SH, Pyo J, et al. Imaging features to distinguish malignant and benign branch-duct type intraductal papillary mucinous neoplasms of the pancreas: A meta-analysis. Ann Surg 2014; 259: 72-81.
[18]
Castillo CF. Intraductal papillary mucinous neoplasms of the pancreas: a plea for prospective differentiation between main-duct and sidebranch tumors. Ann Surg Oncol 2005; 12: 98-9.
[19]
Xu W, Liu X, Zhang J, et al. Intraductal papillary mucinous neoplasms of the pancreas: Correlation of helical Computed Tomography (CT) features with pathologic findings. Acad Radiol 2017; 24(5): 609-14.
Download PDF Flyer